Daraxonrasib Extends Survival in Pancreatic Cancer Trial
TL;DR Summary
In an expanded-access trial of the FDA-approved pancreatic cancer drug daraxonrasib, patients showed median survival roughly doubling from 6.7 to 13.2 months and tumor shrinkage, with a South Portland man reporting improved quality of life.
- New pancreatic cancer drug gives South Portland man hope for longer life Portland Press Herald - Maine Sunday Telegram
- FDA approves daraxonrasib for metastatic pancreatic cancer following landmark clinical trial led by Dana-Farber News-Medical
- Daraxonrasib Demonstrates Initial Antitumor Activity in RAS-Mutant Lung Cancer | Newswise Newswise
- Why Revolution Medicines, the Drugmaker Behind a Pancreatic Cancer Breakthrough, Stayed Independent WSJ
Reading Insights
Total Reads
0
Unique Readers
6
Time Saved
2 min
vs 3 min read
Condensed
91%
403 → 35 words
Want the full story? Read the original article
Read on Portland Press Herald - Maine Sunday Telegram